N/A
N=45
Carnosine Loading and Periodized Training in MS and HC
Multiple Sclerosis · Exercise Therapy · Dietary Supplement
Bottom Line
View on ClinicalTrials.gov: NCT03418376 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcome: Primary: VO2max — 40.4; 41.2; 44; 43.4 ml/kg/min
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Beta-alanine supplementation (Dietary_supplement); Exercise intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Hasselt University
- Primary completion
- Oct 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY VO2max |
40.4; 41.2; 44; 43.4 | — |
| PRIMARY Serum Lactate |
4.6; 4.4; 5.0; 5.1; 8.5; 9.2 | — |
| PRIMARY Body Composition |
51.4; 49.2; 55.7; 50.3; 16.8; 15.5 | — |
| PRIMARY Strength Assessment Core Musculature |
257.4; 243.3; 243.5; 256; 132.7; 145.3 | — |
| PRIMARY Workload |
209; 212; 248; 235 | — |
Summary
Increasing evidence favours exercise therapy as an efficient tool to counteract inactivity related secondary symptoms in MS. Furthermore, exercise therapy may affect MS-associated muscle contractile and energy supply dysfunctions. So far, low to moderate intensity exercise rehabilitation has shown to induce small but consistent improvements in several functional parameters. High intensity exercise training in MS seems to further improve this. However, although results are promising, impairments in both muscle contraction and energy supply probably attenuate therapy outcome. In keeping with the above described physiological role of skeletal muscle carnosine and because muscle carnosine content may be lower in MS, the primary aim of the present project is to investigate whether carnosine loading improves exercise therapy outcome (exercise capacity, body composition) and performance in MS. If the latter hypothesis can be confirmed, muscle carnosine loading could be a novel intervention to improve exercise capacity and muscle function in this population.
Eligibility Criteria
Inclusion criteria
Diagnosis Multiple Sclerosis. Healthy control. Aged >18y. Written informed consent.
Exclusion criteria
Contraindications to perform moderate to high intensity exercise. Participation in another study. Experienced acute MS related exacerbation 3.5
Data sourced from ClinicalTrials.gov (NCT03418376). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.